Insmed.pl - Insmed - Life-Transforming Medicines for Serious and Rare Diseases

insmed.com

https://insmed.com/

At Insmed, we make a difference in the lives of patients with serious & rare diseases through innovative drug development & a patient-first culture.

DA: 88 PA: 29 MOZ Rank: 23

insmed.com

https://grant.insmed.com/

Insmed is dedicated to the advancement of philanthropic causes that are consistent with Insmed’s scientific and disease areas of interest. Donations may be used for patient/caregiver …

DA: 76 PA: 6 MOZ Rank: 11

yahoo.com

https://finance.yahoo.com/quote/INSM

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will … Ask: 26.22 x 1000 Open: 26.36 Bid: 25.00 x 800 Previous Close: 26.43

Ask: 26.22 x 1000

Open: 26.36

Bid: 25.00 x 800

Previous Close: 26.43

DA: 54 PA: 41 MOZ Rank: 65

insmed.com

https://investor.insmed.com/2022-02-17-Insmed-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Business-and-Pipeline-Update

Feb 17, 2022 · Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial …

DA: 10 PA: 1 MOZ Rank: 30

insmed.com

https://2021annualreport.insmed.com/

Annual Shareholder Meeting. To be held on May 11, 2022, at 9:00 a.m. ET. Shareholders may receive without charge a copy of our Annual Report on Form 10-K for the year ended …

DA: 13 PA: 62 MOZ Rank: 53

yahoo.com

https://finance.yahoo.com/quote/INSM/news/

Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DA: 3 PA: 66 MOZ Rank: 56

marketbeat.com

https://www.marketbeat.com/stocks/NASDAQ/INSM/

Sep 22, 2022 · Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome …

DA: 34 PA: 38 MOZ Rank: 75

linkedin.com

https://www.linkedin.com/jobs/view/biotech-sales-representative-orange-county-los-angeles-south-at-insmed-incorporated-2898269551

Insmed is a growing global biopharmaceutical company powered by our purpose to deliver life-altering therapies to small patient populations experiencing big health problems.

DA: 90 PA: 48 MOZ Rank: 5

yahoo.com

https://finance.yahoo.com/quote/INSM

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022.

DA: 81 PA: 26 MOZ Rank: 78

insmed.com

https://investor.insmed.com/index

/Investors Investors Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do.

DA: 69 PA: 3 MOZ Rank: 3

insmed.com

https://insmed.com/about/

Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth. no-month 2018 Insmed is granted accelerated approval by the FDA for its first therapy. no-month 2018 Insmed submits a New Drug Application to the FDA for its lead product candidate. no-month 2017

DA: 56 PA: 39 MOZ Rank: 95

insmed.com

https://insmed.com/about/

Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline. no-month 2013 Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.

DA: 53 PA: 38 MOZ Rank: 60